Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : WK369
Catalog No.: PC-21609Not For Human Use, Lab Use Only.
WK369 (WK-369) is a specific small molecule inhibitor of BCL6, directly binds to the BCL6-BTB domain (SPR KD=2.24 uM) and blocks the interaction between BCL6 and SMRT with IC50 of 0.32 uM in HTRF assays.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
WK369 (WK-369) is a specific small molecule inhibitor of BCL6, directly binds to the BCL6-BTB domain (SPR KD=2.24 uM) and blocks the interaction between BCL6 and SMRT with IC50 of 0.32 uM in HTRF assays.
WK369 exhibits excellent binding affinities to BCL6-BTB domain with IC50 of <2 uM in HTRF assays, 120 times higher potent than that of FX1 (Cat# PC-60927).
WK369 inhibits the transcriptional repressor activity of BCL6-BTB in a dose dependent manner in vitro and in vivo, but without any effect on the other BTB zinc finger repressors (Kaiso and PLZF).
WK369 significantly reactivates multiple BCL6-target genes including ATR, CD69, p53 and CDKN1A.
WK369 inhibits ovarian cancer cell growth, migration and induces apoptosis.
WK369 prevents ovarian cancer growth, suppresses ovarian cancer intra-abdominal metastasis in vivo.
WK369 sensitizes ovarian cancer to chemotherapy on SKOV3 xenograft mouse models, inhibits AKT and MEK/ERK signaling pathway by targeting BCL6.
| M.Wt | 369.40 | |
| Formula | C19H20FN5O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Min Wu, et al. Int J Biol Sci. 2024 Jan 1;20(2):486-501.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
